Live Breaking News & Updates on Cardiovascular Business Development|Page 8

Stay updated with breaking news from Cardiovascular business development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novo nabs Cardior in €1B deal, gaining phase II-stage miRNA drug

In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease. ....

Claudia Ulbrich , Novo Nordisk , Cardior Pharmaceuticals Gmb , Pharmaceuticals Gmbh , Novo Nordiska S , Cardior Pharmaceuticals Gmbh , Cdr 132l , Heart Disease , Mir 132 , Deals Andm Amp A , Mir 132 Inhibitor , Noncoding Rna , Heart Failure , Cardiac Hypertrophy ,

FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures

This expansion applies to the estimated 70 million patients who need either primary or secondary prevention, regardless of statin use. ....

Sheldon Koenig , European Medicines Agency , Committee For Medicinal Products Human , Esperion Therapeutic , Olivier Le Moal , Medicinal Products , Heart Attack , Fda Approval ,

Biosense Webster continues PFA approval trend, nabs CE mark for Varipulse

Continuing the spate of regulatory approvals for pulsed field ablation (PFA) devices around the world, Johnson & Johnson’s Biosense Webster Inc. unit secured CE mark for the Varipulse platform for treatment of symptomatic, drug-refractory recurrent paroxysmal atrial fibrillation. ....

Johnson Biosense Webster Inc , Biosense Webster , Bioworld Medtech , Biosense Webster Inc , Face Mark , Johnson Amp , Boston Scientific Corp , Medtronic Plc , Farapulse Inc , Thermacool Smarttouch , Atrial Fibrillation , Radio Frequency Ablation ,

First heart centre set up in Eldoret amid rising cardiovascular cases

First heart centre set up in Eldoret amid rising cardiovascular cases ....

Nairobi Area , Rift Valley , Felix Barasa , Moi University , Moi Teaching , Referral Hospital , Heart Disease , Heart Attadck , Heart Centre ,

There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo. ....

United States , Wolfram Doehner , Olivier Le Moal , American Journal , Managed Care , Intern Emerg , Eurj Heart , Heart Fail , Heart Failure , Sglt2 Inhibitor , Internal And Emergency Medicine ,